Wang Y, et al. - Researchers prospectively examined patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) (n=1,324) who received immunochemotherapy to determine the rate as well as consequence of late relapses that occurred following event-free survival at 24 months (EFS24). In this study, EFS24 was achieved by a total of 847 patients, in whom, the estimated cumulative incidence of late relapse was 6.9%, 9.3%, and 10.3% at 3 years, 5 years, and at 8 years after EFS24, respectively. A higher rate of late relapse was found in patients with DLBCL with concurrent indolent lymphoma and those with the germinal center B-cell–like subtype, due to increased relapses with indolent lymphoma. A worse prognosis was observed in patients who relapsed with DLBCL vs those who relapsed with indolent lymphoma.